AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT06367413 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: NAC
Description: Participants will receive three servings of N-acetylcysteine per day during the 4-day experimental period. In specific, they will be supplemented with 13.33 mg of N-acetylcysteine per kg of body weight per serving (40 mg NAC/kg BW/day).
Study NCT06367413 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: NAC + Whey Protein
Description: Participants will receive three servings of N-acetylcysteine + whey protein per day during the 4-day experimental period. In specific, they will be supplemented with 0.31 gr of whey protein and 13.33 mg of N-acetylcysteine per kg of body weight in the first two servings (at mid-morning and mid-afternoon supplements) and with 0.49 gr of whey protein and 13.33 mg of N-acetylcysteine per kg of body weight in the pre-sleep serving (1.1 gr Whey protein + 40 mg NAC /kg BW/day).
Study NCT05194059 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Home-based physical activity
Description: Participants will follow a personalized activity pacing program
Study NCT06560775 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Standard Treatment for SLE
Description: Standard Treatment for SLE
Study NCT06560775 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: PLACEBO_COMPARATOR
Intervention: Standard Treatment for SLE
Description: Standard Treatment for SLE
Study NCT06545890 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine
Description: continous infusion during surgery
Study NCT06545890 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Description: continous infusion during surgery
Study NCT05351749 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: New-prescription Alert
Description: An enhanced drug alert notification in the Michigan Medicine electronic health record (EHR) that is tailored to the specific type of inappropriate Direct Oral Anticoagulant (DOAC) use (e.g., dosing too high for renal dysfunction) and offers decision support to the prescriber to alter a newly prescribed DOAC prescription.
Study NCT05351749 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: New-prescription Alert with referral option
Description: An enhanced drug alert notification in the EHR that is tailored to the specific type of inappropriate DOAC use (e.g., dosing too high for renal dysfunction) and offers decision support to the prescriber to alter new DOAC prescription. This alert will ALSO include an option for referral to the anticoagulation clinic pharmacist for assistance.
Study NCT05351749 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Existing-prescription notification to prescriber
Description: Prescriber receives a notification through the EHR indicating an existing DOAC prescription may not be appropriate (e.g. due to renal function change, new drug-drug interactions), and recommending a prescription update.
Study NCT05351749 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Existing-prescription notification to pharmacist
Description: Pharmacist receives a notification through the EHR indicating an existing DOAC prescription may not be appropriate (e.g. due to renal function change, new drug-drug interactions), and recommending a prescription update.
Study NCT05520710 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Rehabilitation
Description: A strategy-focused intervention aimed at improving everyday cognitive function, structured to maximize treatment dose over a short time period. The shorter time period of the treatment therapy is relative to the one and only current randomized controlled trial of cognitive rehabilitation for military mTBI, the Study of Cognitive Rehabilitation Effectiveness (SCORE).
Study NCT05520710 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Education
Description: Educational materials, designed to help people with traumatic brain injury manage their everyday cognitive challenges will be provided through Zoom video conferencing software.
Study NCT05920902 — intervention group
Intervention type: OTHER
Intervention: routine therapy of acute ischemia stroke
Description: Routine therapy of acute ischemia stroke based on the guidelines, which generally includes two parts: evaluation and medicine treatment. Evaluation includes peripheral blood test, radiologic examination, electrophysiological examination, ultrasonic examination. Medicine treatment includes drug therapy and rehabilitation.
Study NCT05361902 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Adaptive radiotherapy according to UPRATE protocol
Description: According to previously reported STAMPEDE trial (Parker et al.), patients will be treated with 6 weekly fractions of 6 Gy. According to local protocol the target will consist of prostate and entire seminal vesicles. Additional CT-scans will be made prior to and directly following each fraction. For more details, see study description
Study NCT06206343 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: TENS application, Tele-rehabilitation treatment program
Description: Exercise training
Study NCT05334810 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DP303c
Description: DP303c injection, 3.0 mg/kg, every 3 weeks.
Study NCT04028674 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Laryngeal Pacing Device
Description: Device is an implantable neurostimulation system designed to deliver low-intensity electrical impulses to nerve structures.
Study NCT04028674 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Laryngeal Pacing Device
Description: Device is an implantable neurostimulation system designed to deliver low-intensity electrical impulses to nerve structures.
Study NCT04930094 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Secukinumab 300 mg
Description: Secukinumab 300 mg
Study NCT05615974 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LM101
Description: Administered intravenously
Study NCT05615974 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Toripalimab
Description: Administered intravenously
Study NCT05615974 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Administered intravenously
Study NCT04930094 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT04930094 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Secukinumab 150 mg
Description: Secukinumab
Study NCT06553872 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pirtobrutinib
Description: Pirtobrutinib is a non-covalent BTKi that has preserved activity in the presence of mutations that drive BTKi resistance.
Study NCT05624034 — intervention group
Intervention type: DEVICE
Intervention: Electrogastrography
Description: Electrogastrography is used to study abnormalities in healthy subjects and in patients with Diabetic and Idiopathic Gastroparesis
Study NCT05312060 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PC Pneumatic compression
Description: Pneumatic compression of the operated limb
Study NCT04859517 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ADG20
Description: Single dose of ADG20
Study NCT04859517 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Single dose of placebo
Study NCT04782739 — intervention group
Intervention type: OTHER
Intervention: None - Descriptive study
Description: Descriptive study
Study NCT06553872 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brexucabtagene Autoleucel
Description: Brexucabtagene autoleucel is an autologous CD19-directed chimeric antigen receptor (CAR) T-cell therapy (brexu-cel).
Study NCT05312060 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: AE Antithromboembolic exercises
Description: Exercises for the edema
Study NCT05212142 — intervention group
Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: verbal education
Description: Participants will receive oral health anticipatory guidance in the form of verbal and written education alongside the same preventive follow up and recall appointment schedule.
Study NCT05212142 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: verbal education, visual aids, and motivational interviewing
Description: Participants will receive oral health anticipatory guidance through a combination preventive strategy using motivational interviewing, individualized goal setting, visual aids, and verbal education alongside a preventive follow up and recall appointment schedule
Study NCT05123417 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Follow up
Description: Each group participants will be tested with questionnaire before the training and two weeks after the training they will get post test with the same questionnaire.
Study NCT04121013 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: mothership
Description: Randomized controlled study: allocation to active or no intervention arm will be done accordingly to the design temporal sequence
Study NCT06505642 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: needle-based confocal laser endomicroscopy
Description: needle-based confocal laser endomicroscopy at the tip of the TBNA needle for two punctures, combined with confirmatory CBCT spin for tool-in-lesion confirmation
Study NCT05235607 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tumor antigen-sensitized DC vaccine and their sensitized T cells subcutaneous administration
Description: subcutaneous administration
Study NCT05455398 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgical treatment of round window niche enlargement via round window for inner ear drug delivery
Description: The round window niche is surgically removed and the hormone is slowly released into the inner ear using a gelatin sponge that has absorbed the hormone in the round window
Study NCT05455398 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Drum chamber drug injection
Description: Injection of drugs into the tympanic chamber through the tympanic membrane
Study NCT06439290 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Mastectomy/breast augmentation
Description: Control group of PFAB and PMAB persons undergoing a mastectomy or breast augmentation surgery.
Study NCT06345820 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Evolux
Description: Evolux, enhanced monofocal IOL
Study NCT06345820 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Tecnis Eyhance
Description: Tecnis Eyhance, enhanced monofocal IOL
Study NCT06322498 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Uterine lavage
Description: Infusion of 2ml 0.9%NACL into the uterine cavity and aspiration of the fluid
Study NCT06530095 — intervention group
Intervention type: OTHER
Intervention: prone positioning
Description: prone positioning
Study NCT05827991 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 1565nm Non-ablative Fractional Laser
Description: 1565nm Non-ablative Fractional Laser is used for treatment once every 2 weeks, a total of 10 times. 1565nm Non-ablative Fractional Laser uses square and rectangular light spots, and the size is adjusted according to the treatment area, which is about 8-16mm, 250-300spot, 10J/cm2.
Study NCT05827991 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 5% minoxidil external use
Description: The method of use of 5% minoxidil tincture is for topical use on the scalp, 1 ml per time, 2 times per day.
Study NCT05827991 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: 1565nm Non-ablative Fractional Laser combined with 5% minoxidil
Description: The two treatment mentioned above
Study NCT05352191 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Beclomethasone
Description: inhaled 800ug
Study NCT05352191 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Beclomethasone
Description: inhaled 800ug
Study NCT06196307 — intervention group
Intervention type: COMBINATION_PRODUCT
Intervention: Clinical evaluation, laboratory and cardiac imaging results, medication, surgery, and any hospitalization
Description: Examination： Electrocardiogram、 imaging examination、 X-ray, CTA, bedside echocardiography.~History of cardiovascular and pulmonary vascular drug therapy: Antithrombotic therapy (type, measurement) , Anticoagulation therapy (type, metering), Other drug treatments (type, measurement)
Study NCT05137054 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Linvoseltamab
Description: Linvoseltamab is administered by intravenous (IV) infusion
Study NCT05268848 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Thermographic photo
Description: Barefoot patient, thermographic photo of the sole of the feet is taken
Study NCT05268848 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Thermographic photo
Description: Barefoot patient, thermographic photo of the sole of the feet is taken
Study NCT04689308 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MH048
Description: Soft gel capsules 5 mg and 25 mg，oral MH048 should be administered after an overnight fast.
Study NCT04775823 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Hybrid composite nano-ceramic
Description: Indirect bonding the hybrid composite nano-ceramic restoration to the tooth to be restored of worn dentition patients
Study NCT05137054 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daratumumab
Description: Daratumumab is administered by IV infusion and/or subcutaneous (SC) injection; SC injection may be used after a minimum of 2 cycles of IV administration at the investigator's discretion.
Study NCT05137054 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carfilzomib
Description: Carfilzomib is administered by IV infusion
Study NCT05137054 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Lenalidomide is administered by mouth (PO) as a capsule
Study NCT05137054 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib
Description: Bortezomib is administered by IV infusion or SC injection
Study NCT05137054 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pomalidomide
Description: Pomalidomide is administered by mouth (PO) as a capsule
Study NCT05137054 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Isatuximab
Description: Isatuximab is administered by IV infusion
Study NCT05137054 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fianlimab
Description: Fianlimab is administered by IV infusion
Study NCT05137054 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cemiplimab
Description: Cemiplimab is administered by IV infusion
Study NCT05137054 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nirogacestat
Description: Nirogacestat is administered by mouth (PO) as a tablet
Study NCT05912426 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Reduced-sodium potassium-enriched salt
Description: Supply and use of a reduced-sodium, potassium-enriched iodised salt (66% potassium chloride, 34% sodium chloride).
Study NCT05904093 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fostamatinib
Description: Fostamatinib will be administered orally, at a dose of 100 mg twice a day for 14 days and if tolerated, will be escalated to a dose of 150 mg, orally, twice a day for 28 days (total 42 days).
Study NCT05441813 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Virgin Coconut Oil
Description: Standard of care with the addition of virgin coconut oil mouth rinse
Study NCT06349980 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HLX53 (1000mg)
Description: HLX53 will be administered by IV infusion at a fixed dose of 1000 mg on Day 1 of each 21-day cycle.
Study NCT06475404 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: verenafusp alfa 6 mg/kg
Description: Single intravenous administration of 6 mg/kg of verenafusp alfa
Study NCT06475404 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: verenafusp alfa 9 mg/kg
Description: Single intravenous administration of 9 mg/kg of verenafusp alfa
Study NCT06475404 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: verenafusp alfa 12 mg/kg
Description: Single intravenous administration of 12 mg/kg of verenafusp alfa
Study NCT06349980 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HLX53 (2000mg)
Description: HLX53 will be administered by IV infusion at a fixed dose of 2000 mg on Day 1 of each 21-day cycle.
Study NCT06349980 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HLX10
Description: HLX10 will be administered by IV infusion at a fixed dose of 300 mg on Day 1 of each 21-day cycle.
Study NCT06349980 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: HLX10
Description: HLX10 will be administered by IV infusion at a fixed dose of 300 mg on Day 1 of each 21-day cycle.
Study NCT06349980 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HLX04
Description: HLX04 will be administered by IV infusion at a dose of 15 mg/kg on Day 1 of each 21-day cycle.
Study NCT06349980 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: HLX04
Description: HLX04 will be administered by IV infusion at a dose of 15 mg/kg on Day 1 of each 21-day cycle.
Study NCT06349980 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo matching HLX53 will be administered by IV infusion on Day 1 of each 21-day cycle.
Study NCT06448221 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: a web-based Relationship Teaching(RT)/communication education programs
Description: receives the RT program and uses 3 months' smartphone-based videoconferencing without the HEA system.
Study NCT06448221 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Helper of Emotional Assessment Relationship Teaching (HEART) program
Description: receives the RT program and uses 3 months smartphone-based videoconferencing along with the HEA system
Study NCT06542458 — intervention group
Intervention type: BEHAVIORAL
Intervention: Assessments
Description: Participants will undergo a standard battery of neuropsychological measures, behavioral questionnaire, and functional assessment to monitor cognition and function over time. Clinical data obtained as part of standard of care will be collected from the medical record
Study NCT06542458 — intervention group
Intervention type: OTHER
Intervention: Neuroimaging volumetric measures
Description: Neuroimaging volumetric measures will be obtained from already conducted standard of care neuroimaging.
Study NCT06542458 — intervention group
Intervention type: OTHER
Intervention: Biofluid samples
Description: Biofluid sampling data will be obtained through another protocol. All participants will be required to sign that consent to participate in this trial.
Study NCT06562764 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Counselling by the Trained Pharmacist
Description: The intervention group 1 is verbally counselled about the proper use of their inhaler devices.
Study NCT06562764 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pictograms Cards and Counselling by the Trained Pharmacist
Description: The investigator developed pictogram cards for the use of inhalers (MDI and DPI) and pictogram cards are attached to the inhalers of patients in the intervention group with counselling by the trained pharmacist.
Study NCT05138003 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: cardiac MRI
Description: T1 and T2 relaxation times will be evaluated on basal and mid-cavity SA maps; a single ROI measurement in the septum will be manually drawn sufficiently far from tissue interfaces to avoid the impact of susceptibility artifacts from adjacent tissues. The differences in T1 and T2 relaxation times between rest and post-exercise will be analyzed.~Cardiac ventricular volumes, function and LV mass will also be quantified.
Study NCT05138003 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Echocardiography
Description: Measurements of mass, volumes and function will be obtained of both the left and right ventricles enabling comparisons with cardiac MRI and traditional echo measures.
Study NCT05138003 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: RootiRx for the ECG monitoring during the cycling ride
Description: The final report will include the amount of recorded beats, the average heart rate, the maximum and minimum heart rate, the amount of cardiac pauses defined as an interruption in the ventricular rate > 2 seconds. Reported atrial events include atrial ectopic beats and supraventricular tachycardia and ventricular events include ventricular ectopic beats, doublets, triplets, bigeminy, trigeminy and ventricular tachycardia.
Study NCT04662593 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Whole Health Program
Description: A mind-body-spirit intervention to improve health and well-being including weight loss.
Study NCT05442385 — intervention group
Intervention type: OTHER
Intervention: Evidence based management
Description: clinical patterns , laboratory investigations , radiology , lines of managements and outcome of each modality of treatment
Study NCT05138003 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Blood sample
Description: Blood sample will be performed 3 to 6 hours after the stage to analyze high-sensitivity cardiac Troponin T (high-sensitivity) levels, Creatine Phosphokinase (CPK) to eliminate the hypothesis of Troponin elevation induced by rhabdomyolysis and C-reactive Protein to corroborate the inflammatory aspect if there is any.
Study NCT06210633 — intervention group
Intervention type: OTHER
Intervention: medical management
Description: Medical management includes IV thrombolysis, antiplatelet, and/or anticoagulation.